Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 07, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share plan transactions. Key transaction details include:
- Share Prices: Ordinary shares at £11.66 per share and Ordinary Share ADRs at $37.32 per ADR (for the January 2009 dividend reinvestment).
- Share Prices (Prior): Ordinary shares at £11.67 per share (for the October 2008 dividend reinvestment).
- Transaction Type: Notional increases in share interests following the reinvestment of dividends.
Material Changes
The filing details specific increases in notional share interests for various executives following dividend reinvestments. Notable increases include:
- Mr. A P Witty: 5,625.13 Ordinary shares (Jan 2009 dividend) and 690.66 Ordinary shares (Oct 2008 dividend).
- Mr. J S Heslop: 3,959.53 Ordinary shares.
- Dr. M M Slaoui: 352.25 Ordinary shares and 1,835.07 ADRs.
The filing does not provide comparative financial performance data versus prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period. No specific risks or contingencies are disclosed in this document.
Investor Verification Checklist
- Verify the vesting schedule and conditions for the GlaxoSmithKline Performance Share Plan to understand when notional holdings convert to actual equity.
- Confirm the total number of shares held by key executives (e.g., Mr. Witty, Dr. Slaoui) by cross-referencing with previous filings, as this report only lists incremental notional increases.
- Review the company's Form 20-F for comprehensive financial results, as this Form 6-K contains no financial statements.